Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) is expected to release its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to post earnings of ($0.45) per share and revenue of $79.3640 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.11. The company had revenue of $64.86 million for the quarter, compared to analyst estimates of $69.76 million. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 256.65%. The firm’s revenue was up 224.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.98) earnings per share. On average, analysts expect Syndax Pharmaceuticals to post $-2 EPS for the current fiscal year and $-0 EPS for the next fiscal year.
Syndax Pharmaceuticals Stock Performance
NASDAQ SNDX opened at $20.81 on Monday. The stock has a 50-day simple moving average of $20.45 and a two-hundred day simple moving average of $21.46. The firm has a market capitalization of $1.84 billion, a P/E ratio of -7.46 and a beta of 0.37. Syndax Pharmaceuticals has a fifty-two week low of $9.42 and a fifty-two week high of $25.59. The company has a debt-to-equity ratio of 8.26, a quick ratio of 5.06 and a current ratio of 5.47.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on SNDX
Insider Activity
In related news, CEO Michael A. Metzger sold 32,375 shares of Syndax Pharmaceuticals stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $24.24, for a total value of $784,770.00. Following the completion of the transaction, the chief executive officer owned 484,843 shares in the company, valued at $11,752,594.32. The trade was a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Nicholas A.J. Botwood sold 31,235 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $18.14, for a total value of $566,602.90. Following the completion of the transaction, the chief marketing officer directly owned 60,885 shares of the company’s stock, valued at $1,104,453.90. The trade was a 33.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 105,914 shares of company stock worth $2,120,789. Corporate insiders own 4.80% of the company’s stock.
Institutional Trading of Syndax Pharmaceuticals
Institutional investors have recently bought and sold shares of the business. State Street Corp raised its stake in shares of Syndax Pharmaceuticals by 19.3% during the 4th quarter. State Street Corp now owns 4,596,552 shares of the company’s stock worth $96,574,000 after buying an additional 743,003 shares during the period. Bank of America Corp DE grew its stake in Syndax Pharmaceuticals by 33.7% in the 2nd quarter. Bank of America Corp DE now owns 3,838,872 shares of the company’s stock valued at $35,951,000 after acquiring an additional 967,873 shares during the period. Franklin Resources Inc. grew its stake in Syndax Pharmaceuticals by 1.3% in the 4th quarter. Franklin Resources Inc. now owns 2,421,666 shares of the company’s stock valued at $50,879,000 after acquiring an additional 31,105 shares during the period. Soleus Capital Management L.P. increased its holdings in Syndax Pharmaceuticals by 11.7% in the 4th quarter. Soleus Capital Management L.P. now owns 2,247,110 shares of the company’s stock worth $47,212,000 after acquiring an additional 235,000 shares in the last quarter. Finally, Qube Research & Technologies Ltd increased its holdings in Syndax Pharmaceuticals by 99.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,665,916 shares of the company’s stock worth $15,601,000 after acquiring an additional 831,067 shares in the last quarter.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.
The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.
Read More
- Five stocks we like better than Syndax Pharmaceuticals
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
